LXRX – Lexicon Pharmaceuticals Inc.
LXRX
$1.86Name : Lexicon Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $828,136,256.00
EPSttm : -0.15
Lexicon Pharmaceuticals, Inc.
$1.86
LXRX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
12.19
Margin Of Safety %
Put/Call OI Ratio
0.06
EPS Next Q Diff
-0.02
EPS Last/This Y
-0.03
EPS This/Next Y
-0.02
Price
1.88
Target Price
4.51
Analyst Recom
1.67
Performance Q
-20.85
Upside
-204.8%
Beta
1.05
Ticker: LXRX
22 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-12 | LXRX | 1.645 | 0.05 | 0.23 | 31469 |
| 2026-10-13 | LXRX | 1.61 | 0.06 | 0.06 | 31531 |
| 2026-10-14 | LXRX | 1.595 | 0.05 | 0.65 | 31418 |
| 2026-10-15 | LXRX | 1.645 | 0.05 | 0.00 | 31467 |
| 2026-10-16 | LXRX | 1.525 | 0.05 | 0.14 | 31348 |
| 2026-10-19 | LXRX | 1.54 | 0.05 | 0.23 | 25781 |
| 2026-10-20 | LXRX | 1.57 | 0.05 | 0.00 | 25858 |
| 2026-10-21 | LXRX | 1.555 | 0.05 | 0.00 | 25892 |
| 2026-10-22 | LXRX | 1.48 | 0.05 | 0.00 | 25901 |
| 2026-10-23 | LXRX | 1.415 | 0.05 | 0.14 | 25911 |
| 2026-10-26 | LXRX | 1.445 | 0.05 | 1.03 | 26271 |
| 2026-10-27 | LXRX | 1.465 | 0.05 | 18.00 | 26330 |
| 2026-10-28 | LXRX | 1.49 | 0.06 | 2.13 | 26366 |
| 2026-10-29 | LXRX | 1.49 | 0.06 | 0.36 | 26424 |
| 2026-10-30 | LXRX | 1.43 | 0.06 | 0.00 | 26382 |
| 2026-11-02 | LXRX | 1.435 | 0.06 | 0.03 | 26438 |
| 2026-11-03 | LXRX | 1.465 | 0.06 | 0.00 | 26641 |
| 2026-11-04 | LXRX | 1.485 | 0.06 | 0.05 | 26651 |
| 2026-11-05 | LXRX | 1.615 | 0.06 | 0.02 | 26671 |
| 2026-11-06 | LXRX | 1.77 | 0.06 | 0.89 | 26797 |
| 2026-11-09 | LXRX | 1.83 | 0.06 | 0.45 | 27321 |
| 2026-11-10 | LXRX | 1.875 | 0.06 | 0.09 | 27612 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
22 items
«
‹
Current Page1 of 1
›
»
22 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-12 | LXRX | 1.64 | -32.2 | - | -0.17 |
| 2026-10-13 | LXRX | 1.61 | -32.2 | - | -0.17 |
| 2026-10-14 | LXRX | 1.60 | -32.2 | - | -0.17 |
| 2026-10-15 | LXRX | 1.64 | -32.2 | - | -0.17 |
| 2026-10-16 | LXRX | 1.52 | -32.2 | - | -0.17 |
| 2026-10-19 | LXRX | 1.54 | -32.2 | - | -0.17 |
| 2026-10-20 | LXRX | 1.54 | -32.2 | - | -0.17 |
| 2026-10-21 | LXRX | 1.57 | -32.2 | - | -0.17 |
| 2026-10-22 | LXRX | 1.48 | -32.2 | - | -0.17 |
| 2026-10-23 | LXRX | 1.41 | -32.2 | - | -0.17 |
| 2026-10-26 | LXRX | 1.44 | -32.2 | - | -0.17 |
| 2026-10-27 | LXRX | 1.47 | -32.2 | - | -0.17 |
| 2026-10-28 | LXRX | 1.49 | -32.2 | - | -0.17 |
| 2026-10-29 | LXRX | 1.49 | -32.2 | - | -0.17 |
| 2026-10-30 | LXRX | 1.43 | -32.2 | - | -0.17 |
| 2026-11-02 | LXRX | 1.44 | -32.2 | - | -0.17 |
| 2026-11-03 | LXRX | 1.47 | -32.2 | - | -0.17 |
| 2026-11-04 | LXRX | 1.49 | -32.2 | - | -0.17 |
| 2026-11-05 | LXRX | 1.62 | -32.2 | - | -0.17 |
| 2026-11-06 | LXRX | 1.77 | 9.8 | - | -0.17 |
| 2026-11-09 | LXRX | 1.83 | 9.8 | - | -0.17 |
| 2026-11-10 | LXRX | 1.88 | 9.8 | - | -0.17 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
22 items
«
‹
Current Page1 of 1
›
»
21 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-12 | LXRX | 0.00 | 5.30 | 11.79 |
| 2026-10-13 | LXRX | 0.00 | 5.30 | 11.79 |
| 2026-10-14 | LXRX | 0.00 | 5.30 | 11.79 |
| 2026-10-15 | LXRX | 0.00 | 5.30 | 11.79 |
| 2026-10-16 | LXRX | 0.00 | 5.30 | 11.79 |
| 2026-10-19 | LXRX | 0.00 | 5.39 | 11.79 |
| 2026-10-20 | LXRX | 0.00 | 5.39 | 11.79 |
| 2026-10-21 | LXRX | 0.00 | 5.39 | 11.79 |
| 2026-10-22 | LXRX | 0.00 | 5.39 | 11.79 |
| 2026-10-23 | LXRX | 0.00 | 5.39 | 11.79 |
| 2026-10-26 | LXRX | 0.00 | 5.23 | 11.79 |
| 2026-10-27 | LXRX | 0.00 | 5.23 | 12.19 |
| 2026-10-28 | LXRX | 0.00 | 5.23 | 12.19 |
| 2026-10-29 | LXRX | 0.00 | 5.23 | 12.19 |
| 2026-10-30 | LXRX | 0.00 | 5.23 | 12.19 |
| 2026-11-02 | LXRX | 0.00 | 5.24 | 12.19 |
| 2026-11-03 | LXRX | 0.00 | 5.24 | 12.19 |
| 2026-11-05 | LXRX | 0.00 | 5.24 | 12.19 |
| 2026-11-06 | LXRX | 0.00 | 5.24 | 12.19 |
| 2026-11-09 | LXRX | 0.01 | 4.99 | 12.19 |
| 2026-11-10 | LXRX | 0.01 | 4.99 | 12.19 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
21 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
-0.03
Avg. EPS Est. Current Quarter
-0.04
Avg. EPS Est. Next Quarter
-0.05
Insider Transactions
0.01
Institutional Transactions
4.99
Beta
1.05
Average Sales Estimate Current Quarter
11
Average Sales Estimate Next Quarter
Fair Value
Quality Score
46
Growth Score
30
Sentiment Score
81
Actual DrawDown %
64.5
Max Drawdown 5-Year %
-94.3
Target Price
4.51
P/E
Forward P/E
PEG
P/S
21.49
P/B
5.05
P/Free Cash Flow
EPS
-0.15
Average EPS Est. Cur. Y
-0.17
EPS Next Y. (Est.)
-0.19
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-161.8
Relative Volume
1.3
Return on Equity vs Sector %
-64.4
Return on Equity vs Industry %
-44.6
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
◆
LXRX
Healthcare
$1.86
📉
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
14/20
Pullback
6/25
Volume
3/15
Valuation
12/20
TP/AR
3/10
Options
7/10
RSI
65.3
Range 1M
84.9%
Sup Dist
5%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
8/25
Growth
9/30
Estimates
3/20
Inst/Vol
7/15
Options
10/10
EPS Yr
-13.6%
EPS NY
-32.8%
52W%
48.7%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+142.5% upside
Quality
6/30
Valuation
15/30
Growth
6/25
Stability
6/10
LT Trend
1/5
Upside
+142.5%
Quality
46
Click a card to see score breakdown
Full Analysis →
LXRX — P/E HistoricalBiotechnology
Sector: Healthcare
Industry: Biotechnology
Employees: 81
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
LXRX
Latest News
—
Caricamento notizie per LXRX…
stock quote shares LXRX – Lexicon Pharmaceuticals Inc. Stock Price stock today
news today LXRX – Lexicon Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch LXRX – Lexicon Pharmaceuticals Inc. yahoo finance google finance
stock history LXRX – Lexicon Pharmaceuticals Inc. invest stock market
stock prices LXRX premarket after hours
ticker LXRX fair value insiders trading